Securin Antibody [E2P20]

Catalog No.: F5314

    Application: Reactivity:
    • Lane 1: HT-29, Lane 2: HT-29 (Thymidine, 2 mM, 16 h)
    1/

    当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:1000
    1:200
    Application
    WB, IP
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Human
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW
    25 kDa

    Datasheet & SDS

    生物学的記述

    Specificity
    Securin Antibody [E2P20] detects endogenous levels of total Securin protein.
    Clone
    E2P20
    Synonym(s)
    Securin; Pituitary tumor-transforming gene 1 protein; PTTG1
    Background
    Securin, encoded by the pituitary tumor‑transforming gene 1 (PTTG1), is a multifunctional regulatory protein that governs mitotic checkpoint fidelity, chromosome segregation, and non‑mitotic processes such as migration and gene expression. Securin functions as a dimeric inhibitor that binds and suppresses the protease separase, preventing precocious cleavage of the cohesin complex and thereby holding sister chromatids together until anaphase onset, while distinct domains also support separase‑independent activities that modulate microtubule nucleation, DNA‑repair responses, and p53‑linked transcription. Securin ensures accurate anaphase timing by coordinating the activation of separase with completion of spindle‑attachment and checkpoint satisfaction, and its ubiquitin‑mediated degradation by the anaphase‑promoting complex/cyclosome (APC/C) releases separase to drive cohesin removal and chromosome segregation, defects in which promote aneuploidy and genomic instability. In interphase and migrating cells, cytoplasmic securin localizes to the centrosome and Golgi where it associates with microtubule‑organizing‑center proteins such as GM130, AKAP450, and γ‑tubulin, stimulating microtubule nucleation and remodeling necessary for cell polarization, directed migration, and invasion, and securin overexpression enhances these motile behaviors in cancer models. Securin expression correlates with proliferation status and clinical outcomes, and mouse‑genetic studies show that Pttg1/securin loss predisposes to spontaneous mammary‑gland tumors and disrupts ductal morphogenesis.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください